Background: Few population-based studies assess
INTRODUCTION
There are few incidence studies that include both invasive and in situ melanoma. Population-based studies are often dependent on routine cancer registries and usually exclude in situ disease. Clinically based series may include in situ disease, but are often influenced by referral patterns, raising concerns over their accuracy. Our objective was to study all in situ and invasive excised melanomas in residents of the Waikato region in New Zealand to compare invasive and in situ disease, and to assess incidence by body site. New Zealand, along with Australia, has the highest incidence and mortality rates of invasive melanoma in the world, with New Zealand having the highest rate by disability-adjusted life years. 1 The relationship between in situ and in invasive melanoma is unclear. In situ disease may be an early phase, or a less aggressive form, of melanoma. Examination of the features of these diseases may clarify this.
METHODS
We obtained all records of histopathologically confirmed melanoma from the two laboratories serving Waikato, the District Health Board laboratory and the private laboratory Pathlab, over the 3-year period 2010 to 2012. To ensure completeness, records were checked at hospital clinical services, primary care and private specialists, teledermoscopy services, the District Health Board's Virtual Lesion Clinic and the private skin cancer detection programme Molemap. For patients with multiple lesions, one index lesion was selected as the primary melanoma with the earliest date of excision, and the thickest lesion if more than one lesion had Breslow depth recorded on the same day. Patients retained as in situ melanoma included only those with no invasive melanoma recorded. Data were collected on source of data, age, sex, ethnicity (following New Zealand Ministry of Health ethnicity data protocols), place of residence, body site of the melanoma, Breslow thickness, AJCC stage (7th Edition) 2 and histopathological subtype recorded as lentigo maligna, nodular, superficial spreading and not otherwise specified melanoma. The patient's residential address was geocoded (information was inadequate for 25 patients) and used to calculate the distance to the main hospital, and socio-economic deprivation, classified according to the New Zealand Deprivation Index 2006. 3 This assigns to small residential areas a deprivation decile on a scale of 1-10 based on nine socio-economic variables measured during the 2006 population census; with decile1 being least deprived and decile10 most deprived. Information on clinical care pathways and time intervals was also collected, but not reported here. Data coding and categorisation were done mainly by two investigators (SK, KI) with a consensus of all investigators obtained for the final files. Few data were missing so no imputation was used. Statistical analysis produced incidence rates over the 3-year period by 5-year age groups, with age standardisation to the World Health Organisation world population. As Breslow depth was highly skewed, geometric means were calculated: this is equivalent to the mean of the log-transformed distribution. Body site was coded into 29 sites, from the clinical and surgical notes, with sites recombined for further analysis. Estimated body surface areas were based on a previous study; 4 from these relative tumour density and its confidence limits were calculated. 4 Statistical analysis using cross tabulations and multiple logistic and linear regression was carried out using the SAS statistical package version 9.3.
Ethical approval was given by the National Health and Disability Ethics Committee, 13/NTB/100, 31 July 2013. No patients were approached in this study.
In 2010-2012, Waikato had a census population of 370 986. Histopathological data on 1268 lesions was assessed, of which 201 represented multiple lesions in the same patient over the 3-year period. By ethnicity, all subjects were coded as 'NZ European' ethnicity, except 11 as M aori and 8 'other', but as 142 had no data on ethnicity, all groups are included. There were 9 unusual lesions: 4 acral lentiginous, 1 amelanotic, 3 desmoplastic and 1 spindle cell melanoma, which were excluded as they were too few for specific analysis, and 3 with age unrecorded. After data editing and removal of duplicates, 974 patients were analysed in terms of their first or deepest recorded melanoma. For subtype analyses, 88 cases with no recorded subtype data were excluded.
RESULTS
Incidence of invasive, in situ, and total melanoma Over 3 years, there were 974 patients with a histopathological diagnosis of melanoma, of which 585 (60.1%) were invasive, and 531 (54.5%) were in men. The age range was 22-97 and the median ages were 63 years for women and 69 years for men. 82 (8.4%) patients had more than one melanoma in the 3-year period. Excision rates were highest in December to February (New Zealand summer) and lowest in May to July (winter) but differences were not statistically significant. No time variation was seen over the 3 years.
Incidence rates by age ( Fig. 1) show similar rates in men and women for both invasive and in situ melanoma from age 20 to 59, but higher rates in men than women from age 60; the male excess increases with age. The rates of in situ melanoma are lower than rates of invasive melanoma throughout the age range, but the age patterns are similar. Age standardised rates (WHO world population) were 34.3 per 100 000 for invasive melanoma in females and 41.4 in males, and 20.9 and 27.6 for in situ melanoma, for a total melanoma rate of 55.2 per 100 000 in females and 69.0 in males. These data show a cumulative incidence of total melanoma by age 70 of 4.4% in females and 4.6% in males. Applying these rates to 2018 population data for New Zealand gives an estimated 4200 incident patients, 2500 with invasive and 1700 with in situ melanoma.
Invasive and in situ melanoma
Of all melanomas excised, 39.9% were in-situ disease. The mean age was higher for in situ disease (66.4 years) than for invasive disease (63.8 years, P = 0.007), and this was seen for upper and lower limb and trunk lesions separately, although the differences were not significant (Table 1) . For the head and neck, patients with in situ disease were slightly (non-significant) younger than those with invasive disease.
The proportion of in situ disease was higher on the head and neck (59%, P = 0 < 0.001), but was similar for the trunk (36.1%), lower limb (32.6%) and upper limb (33.5%). It varied little by sex (males 40.5%, females 39.3%). Multivariate analysis (including age, sex and body site) showed that increased age and head and neck location were closely associated. In situ disease relates to pathological classification: for superficial spreading lesions, 7.5% were in situ, compared to 71.1% of unspecified lesions and 84.0% of lentigo maligna lesions (P < 0.001), while no nodular melanomas were in situ.
Breslow thickness
For invasive melanoma, Breslow thickness was measured, and as it is skew distributed, expressed as a geometric mean. Geometric mean for all invasive lesions was 0.80 mm (0.78 mm in women and 0.85 mm in men). After multivariate adjustment, thickness was seen to increase significantly in patients over age 80 years; lesions on the lower limb were thicker than those on the trunk, but sex had no independent effect (Table 2 ). Breslow depth was not associated with the distance of the patient's residence to the main hospital or dermatological centre. A weak trend for increasing depth with greater social deprivation was seen, but this was not statistically significant after adjustment for age and body site. Similar results were given by considering thickness in three groups, ≤1 mm, 1-2.99 mm, and 3+ mm; data not shown here.
Nodular melanoma
Nodular melanoma and thick (>3 mm) melanoma are closely linked, so analyses comparing nodular with all other invasive melanoma shows results consistent with the analyses by depth. Nodular melanoma comprised 15% of invasive melanoma (Table 3) . Geometric mean depth was 3.0 mm (95% limits 2.6-3.5 mm), much thicker than other types of melanoma. Compared to other types, on multivariate analysis, nodular melanoma is more common in patients aged 60-79 and 80+ years compared to 40-59, in males, and on the upper and lower limbs, compared to the trunk.
Further consideration of body site
Body site was classified into 15 regions, and incidence rates relative to the whole body calculated; a ratio of 1.0 means the age-standardised rate per unit area at that body site was the same as the whole body in that sex; a ratio above 1.0 shows a higher rate. Considering invasive and in situ disease together, these ratios ranged from 0.04 and 0.06 (on the buttocks of women and men, respectively), to, for the face, 4.76 for women and 3.69 for men (Fig. 2) .
In general, higher relative incidence is seen on the more usually sun-exposed body sites, with sex differences reflecting this: thus, high relative incidence is seen on the lower and upper limbs, especially in women, and on the shoulder and back in men, while rates on sites usually shielded from the sun are low: buttocks in both sexes; chest and abdomen especially in women, and scalp in women. The low relative rates on the hand in both sexes and on the forearm and wrist in men are unexplained. The areas of the body by relative incidence ratio are also shown in Fig. 3 . Analyses were also done for in situ and invasive lesions separately, with similar results to those shown. The proportion of in situ lesions in these body areas was compared to the relative incidence ratio, in each sex, but no regular association was seen. Relative incidence ratio for a body site = proportion of total cases/proportion of skin area Data ordered by relative incidence ratio in females 
DISCUSSION
Although there have been several previous studies of melanoma in New Zealand, [5] [6] [7] [8] [9] [10] [11] few if any include all biopsied lesions in a defined population and include all in situ and invasive melanoma. This study used multiple sources of information and careful checking of addresses to include all biopsied lesions from a defined population in a defined time period. Patients resident outside the area were excluded. The results for invasive melanoma are very similar to those of the national New Zealand Cancer Registry, which reports only invasive melanoma, but with little clinical detail. Age-standardised rates for 2010-2012 nationally, to the WHO world standard, were 34.2 and 41.3 per 100 000 in women and men, almost identical to the incidence of invasive melanoma reported here of 34.3 and 41.4 respectively; and the pattern of incidence rates by age is virtually identical in these two sources. These national rates equate to 2290 annual new cases of invasive melanoma in these years. It is likely that our observed rates of in situ melanoma are also similar to national rates; adding these suggests that nationally there were 3811 new cases of melanoma and cumulative rates of 1.0% by age 50 and 4.5% by age 70 in 2010-2012. This gives an estimated total cases in 2018, just applying population growth, of 4200. Counting only invasive melanoma severely underestimates the healthcare workload as well as the population anxiety burden of melanoma.
The relationship between in situ and invasive melanoma is unclear. If in situ, early and more advanced melanoma represent time-dependent phases in the evolution of the malignancy, and the likelihood of progression between the states is reasonably similar in all patients, then the features of the three phases of disease at diagnosis, such as the sex and body site distribution, should be similar, whilst the more advanced forms will occur at older ages. However, if these three clinical states are not simply phases of a consistent time-dependent process, the characteristics of patients diagnosed with each of the three conditions may be considerably different. This question has considerable clinical implications. If the biological development of melanoma is a simple and inevitable progressive process, the diagnosis and excision of many early invasive or in situ lesions should lead over time to a reduction in the incidence of more advanced melanoma, and ultimately a reduction in deaths. Thus, the prominent melanoma pathologist Ackerman wrote in 1985 12 that attention to in situ melanoma would lead to: 'simple excision of the lesion and the prevention of the malignant melanoma from evolving into a neoplasm with the potential for metastasis'. However, if the progression process from in situ to early invasive to more advanced melanoma is more complex, and if many early lesions would not progress if left in place, the diagnosis and removal of early disease may not effectively prevent the diagnosis of more advanced lesions and may represent overdiagnosis.
The question is not easily answered, as a trial involving fewer removals of in situ disease would be unethical unless very carefully designed, but descriptive data may be helpful. There seems little descriptive evidence that removing in situ disease leads to a reduction in invasive melanoma incidence. Indeed, in older subjects in the US, the opposite is suggested, with increasing total biopsy rates related to increased in situ and early melanoma with no effect on advanced melanoma. 13 The current analysis shows that patients with in situ melanoma are generally older than those with invasive melanoma. This is more in keeping with the view that melanoma in situ represents a slower growing less aggressive lesion, which may not progress or only progress in a small proportion of cases. The finding that melanoma in situ tends to be diagnosed in older patients than invasive melanoma has been seen in several populations, such as the US. In US cohort studies 14 in situ melanomas were diagnosed at an older age and occurred more often on the head and neck and less frequently on the lower limbs, and on the trunk in men, than invasive disease. Our data showed a higher proportion of in situ disease on the head and neck. Head and neck melanoma is regarded as more likely related to chronic sun exposure, less likely to be associated with naevi, with mutations in KIT or NRAS being more frequent and mutations in BRAF less frequent than on other sites, 15 so in situ disease may be linked to these mechanisms. However, we found no clear differences in in situ disease between trunk and limbs and in a more detailed assessment of body site, no association with relative incidence, although higher relative incidence appeared linked to chronic sun exposure.
Patients diagnosed with in situ melanoma (which is then removed) have an increased subsequent risk of both melanoma in situ and invasive melanoma, 16, 17 showing that it is a marker for increased risk. Subsequent melanomas tend to occur in the same body region. 17 The concept that in situ melanoma and thin melanoma may be particularly increased by increased awareness and examination practice is supported by the observation that over time the incidence rate of in situ melanoma has increased even faster than the incidence of invasive disease. Thus, in Queensland over 20 years 18 in situ melanoma steadily increased in all ages, whilst the incidence of invasive melanoma was stable or decreased in those under 60. At ages 15-24 in Queensland, invasive melanoma has decreased in incidence whilst in situ melanoma has remained stable. 19 The annual increase in in-situ incidence has been greater than that of invasive disease in several European studies e.g. in a combined analysis of 18 European cancer registries. 20 In the US, pathological criteria may have changed; a small US study showed a trend for reclassification of lesions previously classed as non-invasive towards invasive disease after review 20 years later. 21 Compared to previous New Zealand studies, the proportion of invasive melanoma was about the same whilst thick melanoma was slightly more prevalent in our study. Of the invasive melanomas, 60% were 'thin' with a Breslow depth ≤1 mm, whilst 14% were 'thick' melanomas with depths of 3 mm or over. In previous New Zealand studies, the proportion of thin melanomas was 63-66%, and of thick melanomas was 4-11%. [5] [6] [7] [8] [9] [10] [11] In our study, the highest proportion of thin lesions was in the youngest age group (under 40), whilst the proportion of thick melanomas was highest in the oldest age group (over 80 years). These are consistent with some previous studies, 5 but not all. 22 In Australia, the higher proportion of thicker melanoma in older people has been associated with a lower likelihood of older patients detecting changes in melanoma. 23 In this study, the proportion of thin melanomas was higher in females and the proportion of thick melanomas was higher in men, but sex differences did not reach statistical significance. In previous studies, a higher proportion of thick melanomas in men has been found in some 5, 7, 11 but not in all studies. 9 Our study emphasises the importance of nodular melanoma as relating closely to deeply invasive melanoma. Increased thickness in nodular melanomas has previously been reported in New Zealand and internationally. 24 In 404 consecutive Australian patients, the median monthly growth rate, based on time of development and Breslow thickness, of nodular melanomas was 0.49 mm, faster than superficial spreading (0.12 mm) or lentigo maligna melanomas (0.13 mm). 25 In this study, we did not see an association between depth of invasive melanoma and social deprivation or distance from the patient's residence to the main hospital. Associations of thick melanoma with greater distance of travel were found in North Carolina, USA. 26 In a systematic review, associations between low socio-economic status and higher rates of advanced melanoma was seen mainly from studies in the United States. 27 The lack of such associations in our data suggests that health care services for early melanoma are generally equitably distributed in the Waikato region of New Zealand. We have shown that reporting in situ as well as invasive melanoma expands the clinical picture; the combined incidence is over 60% higher than that of invasive disease alone. The generally older age distribution of in situ disease suggests it is a slower growing form, rather than an early phase or precursor of invasive disease. Deeply invasive and nodular melanoma are priorities for prevention and early detection.
